Christine Canman, Ph.D.
Dr. Canman received her B.S. degree in Microbiology from the University of Illinois in 1987 and Ph.D. degree in Pharmacology in 1992 from the University of Michigan. She then trained under the mentorship of Dr. Michael B. Kastan as a postdoctoral fellow at Johns Hopkins University from 1993 - 1998. There she investigated signaling pathways induced by ionizing radiation and mediated by the Ataxia Telangiectasia Mutated protein kinase. Dr. Canman then joined the faculty at St. Jude Children’s Research Hospital as an Assistant Member and continued her research in understanding signaling pathways related to the maintenance of genome stability and responses to ionizing radiation. From 2002-2004, Dr. Canman pursued a new career in Oncology Drug Discovery at Pfizer in Ann Arbor. There, she worked on projects related to the development of tyrosine kinase inhibitors for cancer treatment. In 2004, Dr. Canman became an Assistant Professor in the Department of Pharmacology at the University of Michigan where she continues to investigate cellular mechanisms that promote genome stability and resistance to standard chemotherapeutic agents. In 2012, she was promoted to Associate Professor with tenure.
We investigate how translesion DNA synthesis (TLS) polymerases promote genome stability, tolerate DNA replication stress, and contribute to chemotherapeutic resistance of cancer cells. Currently, our major goal is to determine how TLS polymerases are regulated by the Fanconi anemia pathway and influence the therapeutic response of cells treated DNA crosslinking agents.